156 related articles for article (PubMed ID: 2057176)
1. [Multicenter prospective controlled study of therapy of chronic myeloid leukemia. Comparison of busulfan, hydroxyurea and interferon alpha (April 1990 status)].
Hehlmann R; Heimpel H; Heinze B; Georgii A; Kolb HJ; Hossfeld DK; von Wussow P; Hochhaus A; Griesshammer M; Diehl V
Onkologie; 1991 Feb; 14(1):66-73. PubMed ID: 2057176
[TBL] [Abstract][Full Text] [Related]
2. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
Hehlmann R; Heimpel H; Kolb HJ; Heinze B; Hochhaus A; Griesshammer M; Pralle H; Queisser WP; Essers U; Falge C
Leuk Lymphoma; 1993; 11 Suppl 1():159-68. PubMed ID: 8251890
[TBL] [Abstract][Full Text] [Related]
3. [Chemotherapy of chronic myelocytic leukemia. Status of the German Multicenter Study on busulfan versus hydroxyurea versus alpha interferon, October 1897].
Hehlmann R; Anger B; Messerer D; Zankovich R; Bergmann L; Kolb HJ; Meyer P; Essers U; Queisser U; Vaupel H
Onkologie; 1988 Feb; 11(1):25-9. PubMed ID: 3283622
[TBL] [Abstract][Full Text] [Related]
4. Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha.
Hehlmann R; Anger B; Messerer D; Zankovich R; Bergmann L; Kolb HJ; Meyer P; Essers U; Queisser U; Vaupel H
Blut; 1988 Feb; 56(2):87-91. PubMed ID: 3277680
[TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.
Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Heinze B; Georgii A
Blood; 1993 Jul; 82(2):398-407. PubMed ID: 8329700
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Hochhaus A; Heinze B
Blood; 1994 Dec; 84(12):4064-77. PubMed ID: 7994025
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
Nese M; de Bellis R; Urtiarte R; Di Landro J
Sangre (Barc); 1994 Jun; 39(3):183-6. PubMed ID: 7940047
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia.
Sacchi S; Kantarjian HM; O'Brien S; Beran M; Koller C; Pierce S; Kornblau S; Estey E; Keating MJ; Talpaz M
Leukemia; 1997 Oct; 11(10):1610-6. PubMed ID: 9324278
[TBL] [Abstract][Full Text] [Related]
9. A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
Haematologica; 1992; 77(3):204-14. PubMed ID: 1427426
[TBL] [Abstract][Full Text] [Related]
10. [Treatment with interferon alfa-2a in the chronic phase of Philadelphia-positive chronic myeloid leukemia].
Steegmann JL; Lavilla E; Somolinos N; Pérez-Sánchez M; Lamana M; Olmeda F; Cámara R; Arranz R; Ferro MT; Fernández-Rañada JM
Sangre (Barc); 1992 Oct; 37(5):375-81. PubMed ID: 1293778
[TBL] [Abstract][Full Text] [Related]
11. [Low doses of alpha-interferon preparations in the treatment of patients with chronic myeloleukemia].
Abdulkadyrov KM; Udal'eva VIu; Rukavitsyn OA; Bessmel'tsev SS
Ter Arkh; 2000; 72(7):22-7. PubMed ID: 10983316
[TBL] [Abstract][Full Text] [Related]
12. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.
; Tura S; Baccarani M; Zuffa E; Russo D; Fanin R; Zaccaria A; Fiacchini M
N Engl J Med; 1994 Mar; 330(12):820-5. PubMed ID: 8114834
[TBL] [Abstract][Full Text] [Related]
13. [Prognosis of children with chronic myeloid leukemia: a retrospective analysis of 75 patients].
Creutzig U; Ritter J; Zimmermann M; Klingebiel T
Klin Padiatr; 1996; 208(4):236-41. PubMed ID: 8926689
[TBL] [Abstract][Full Text] [Related]
14. Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group.
Hehlmann R; Heimpel H; Hossfeld DK; Hasford J; Kolb HJ; Löffler H; Pralle H; Queisser W; Hochhaus A; Tichelli A; Fett W; Schmitz N; Reiter A; Griesshammer M; Pfeifer W; Bümler M; Kamp T; Tobler A; Eimermacher H; Kuse R; Berger U; Ansari H
Bone Marrow Transplant; 1996 May; 17 Suppl 3():S21-4. PubMed ID: 8769695
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.
Berger U; Engelich G; Maywald O; Pfirrmann M; Hochhaus A; Reiter A; Metzgeroth G; Gnad U; Hasford J; Heinze B; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Hehlmann R;
Leukemia; 2003 Sep; 17(9):1820-6. PubMed ID: 12970782
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H;
Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239
[TBL] [Abstract][Full Text] [Related]
17. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies.
Berger U; Maywald O; Pfirrmann M; Lahaye T; Hochhaus A; Reiter A; Hasford J; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Hehlmann R;
Leukemia; 2005 Jun; 19(6):984-9. PubMed ID: 15830009
[TBL] [Abstract][Full Text] [Related]
18. A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study.
Giles FJ; Shan J; Chen S; Advani SH; Supandiman I; Aziz Z; Caviles AP; Tee GY; Chasen MR; Fahed Z; Chaoj TY; Aydogdu I; Lynott AM
Leuk Lymphoma; 2000 Apr; 37(3-4):367-77. PubMed ID: 10752988
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of 196 patients with chronic myeloid leukemia based on a standard prognosis model].
Anger B; Schmeiser T; Heimpel H; Robertson J; Sokal JE; Ganser A; Carbonell F
Onkologie; 1990 Apr; 13(2):109-14. PubMed ID: 1695720
[TBL] [Abstract][Full Text] [Related]
20. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM
Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]